BridgeMD
A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 )
EU CTIS ID: 2025-522855-25-00
What this study is testing
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- A type of cancer called urothelial cancer that has spread to other parts of your body and cannot be removed with surgery
- A specific genetic change in the FGFR3 gene that can be found in a tumor or blood sample
- Tumors that can be measured by a doctor using a special system called RECIST v1.1
- Moderate to good level of physical ability
- Adequate laboratory test results
You likely can't join if
- Have already had treatment for cancer that has spread to other parts of your body
- Still have side effects from previous cancer treatment that are worse than mild
- Have nerve damage that affects your senses or movement
- Have cancer that has spread to the brain that is untreated or uncontrolled
- Have eye problems like corneal keratopathy or retinal disorder that are symptomatic or haven't been treated yet
The study team makes the final eligibility decision.
Where it's taking place
- Taiwan
- Canada
- Brazil
- Korea, Republic of
- United Kingdom
- Turkey
- Australia
- China
- Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taiwan; Canada; Brazil; Korea, Republic of; United Kingdom; Turkey and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.